top of page


FDA approves Novo Nordisk Awiqli as first once-weekly basal insulin for children with type 2 diabetes
The FDA has expanded Novo Nordisk's Awiqli approval to children aged 10 years and older with type 2 diabetes, establishing the first once-weekly basal insulin option for this paediatric population.

nuaxia
Oct 282 min read


FDA approves Emcitate as first treatment for MCT8 deficiency
The FDA has approved Emcitate as the first treatment for MCT8 deficiency, providing a therapy for the peripheral thyrotoxicosis associated with this ultra-rare genetic disorder.

nuaxia
Sep 291 min read


FDA approves Onswik as once-weekly basal insulin for adults with type 2 diabetes
The FDA has approved Lilly's Onswik as a once-weekly basal insulin for adults with type 2 diabetes, reducing the frequency of basal insulin injections from daily to weekly dosing.

nuaxia
Sep 252 min read


US Endocrinologist Compensation Reaches $309,782 in Doximity’s 2026 Report
Average annual compensation for US endocrinologists reached $309,782 in Doximity’s 2026 Physician Compensation Report, providing an updated national benchmark for physicians working in endocrinology.

nuaxia
Sep 73 min read


British Columbia Endocrinologist Billings Reach C$539,040, Provincial Analysis Finds
New physician payment data show endocrinologists generated median gross billings of more than C$539,000 in British Columbia.

nuaxia
Aug 183 min read


Vertex Acquires Crinetics for $10B to Expand into Endocrinology
The deal gives Vertex access to a commercial acromegaly therapy and a late-stage rare disease pipeline as the company diversifies beyond cystic fibrosis.

nuaxia
Jul 93 min read


Medscape Endocrinology Compensation Report 2026
Endocrinologists in the US reported modest changes in compensation in 2025, but the broader picture is less about growth and more about stability within a constrained system.

nuaxia
Jun 234 min read
bottom of page